Guided Therapeutics (GTHP) Finished Goods (2011 - 2025)

Guided Therapeutics has disclosed Finished Goods across 15 years of filings, most recently posting $818000.0 for Q1 2025.

• Finished Goods for Q1 2025 came in at $818000.0, up 1759.09% year-over-year; the trailing twelve-month figure through Mar 2025 was $818000.0 (up 1759.09% YoY), and the FY2024 annual result was $818000.0, up 1759.09% from the prior year.
• Finished Goods came in at $818000.0 for Q1 2025 at Guided Therapeutics, roughly flat from $818000.0 in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $818000.0 in Q4 2022 to a low of $32000.0 in Q1 2022.
• The 5-year median for Finished Goods is $758000.0 (2021), against an average of $486588.2.
• Across the five-year window, Finished Goods sank 96.01% in 2021 and jumped 2456.25% in 2023, its largest moves.
• Guided Therapeutics' Finished Goods stood at $785000.0 in 2021, then grew by 4.2% to $818000.0 in 2022, then slumped by 94.62% to $44000.0 in 2023, then jumped by 1759.09% to $818000.0 in 2024, then changed by 0.0% to $818000.0 in 2025.
• The last three Finished Goods figures came in at $818000.0 (Q1 2025), $818000.0 (Q4 2024), and $818000.0 (Q3 2024), per Business Quant data.